Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Insipidus Clear all

Conditions: Blood Loss, Surgical
Interventions: Vasopressin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Social Psychology
Interventions: Intranasal oxytocin, Intranasal vasopressin, Intranasal placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sellar and Suprasellar Masses, Pituitary Tumor
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Septic Shock
Interventions: Angiotensin II, Vasopressin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Sepsis, Septic Shock
Interventions: vasopressin - early initiation, vasopressin - standard initiation; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hyponatremia, Inappropriate ADH Syndrome
Interventions: Satavaptan, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Dehydration
Interventions: Smart Water Bottle; Behavioral
Lead sponsor: Kennesaw State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions: CP101; Biological
Lead sponsor: Finch Research and Development LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 53
States / cities: Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more

Conditions: Type 1 Diabetes, Diabetes Insipidus, Diabetes Mellitus, Wolfram Syndrome
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Traumatic Shock
Interventions: Vasopressin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 707 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Cocaine Dependence
Interventions: Placebo, Intranasal Oxytocin; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Manhattan, New York • The Bronx, New York

Conditions: Work Related Stress
Interventions: Somatic Psychoeducational Intervention; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Arginine Vasopressin Deficiency, Oxytocin Deficiency
Interventions: Norethindrone Acetate-Ethinyl Estradiol; Drug
Lead sponsor: Elizabeth Austen Lawson; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Placebo Analgesia
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Electrolyte Imbalance, Hyponatremia, Hypernatremia
Interventions: V2R (Vasopressin 2 receptor); Drug
Lead sponsor: Oakland University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Rochester, Michigan

Conditions: Water Stress, Body Water Dehydration
Interventions: Hypertonic Saline, Normal Saline; Other
Lead sponsor: University of North Carolina, Greensboro; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Clostridium Difficile Infection Recurrence
Interventions: Full Spectrum Microbiota, Placebo; Drug
Lead sponsor: Finch Research and Development LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 54
States / cities: Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more

Conditions: Dehydration, Diabetes Mellitus, Type 2
Interventions: Water Intake; Other
Lead sponsor: Arizona State University; Other
Eligibility: 30 Years to 55 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: NAFLD
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
Interventions: tolvaptan, placebo matching tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 17 more

Conditions: Acute Pain
Interventions: Arginine vasopressin, Saline, Observational learning, fMRI data aquisition; Drug · Other · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bronchiolitis
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 37 Weeks to 2 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma, Suprasellar Germinoma, Thalamic Germinoma
Interventions: 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Carboplatin, Etoposide, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Questionnaire Administration, Surgical Procedure; Radiation · Procedure · Drug + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 29 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 97
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 76 more

Search by objective public record fields.

Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial

Neuropeptides and Social Behavior

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

Angiotensin II vs. Vasopressin in Septic Shock

Early Versus Late Adjunctive Vasopressin in Septic Shock

A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

Efficacy of a Smart Water Bottle Intervention to Increase Fluid Consumption in College Students

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Tracking Neurodegeneration in Early Wolfram Syndrome

AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock

Biological Basis of Individual Variation in Social Cooperation

Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.

Potential Benefits of the Somatic Psychoeducational Intervention

Identifying Oxytocin Deficiency in Adults With Pituitary Disease

Oxytocin and Arginine Vasopressin in Pain Relief

V2 Receptor Effects on Fluid Regulation and Performance

Influence of Osmotic Stimulation of Vasopressin on Autonomic Function

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers

Copeptin and Nonalcoholic Fatty Liver Disease

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Vasopressin and Pain Perception in the Brain

Atrial and Brain Natriuretic Peptides in Bronchiolitis

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma